# Adriaan A Voors

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4989388/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 576 papers | 73,249 citations | 1171 111 h-index | 693 253 g-index |
| 607 all docs | 607 docs citations | 607 times ranked | 46215 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200. | 1.0 | 13,008 |
| 2 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975. | 2.9 | 5,272 |
| 3 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847. | 1.0 | 5,233 |
| 4 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869. | 2.9 | 2,307 |
| 5 | Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128. | 13.9 | 1,080 |
| 6 | The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395. | 6.3 | 990 |
| 7 | How to diagnose heart failure with preserved ejection fraction: the HFAâ€“PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317. | 1.0 | 944 |
| 8 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, The, 2013, 381, 29-39. | 6.3 | 810 |
| 9 | Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 582-588. | 1.2 | 796 |
| 10 | Angiotensinâ€converting enzyme 2 (<scp>ACE2</scp>), <scp>SARSâ€CoV</scp>â€2 and the pathophysiology of coronavirus disease 2019 (<scp>COVID</scp>â€19). Journal of Pathology, 2020, 251, 228-248. | 2.1 | 791 |
| 11 | Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893. | 13.9 | 753 |
| 12 | Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal, 2014, 35, 455-469. | 1.0 | 747 |
| 13 | EURObservational Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2013, 15, 808-817. | 2.9 | 645 |
| 14 | Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 447-456. | 1.2 | 591 |
| 15 | Outcome of Pregnancy in Women With Congenital Heart Disease. Journal of the American College of Cardiology, 2007, 49, 2303-2311. | 1.2 | 545 |
| 16 | Predictors of pregnancy complications in women with congenital heart disease. European Heart Journal, 2010, 31, 2124-2132. | 1.0 | 538 |
| 17 | Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2007, 13, 599-608. | 0.7 | 527 |
| 18 | Mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 2017, 14, 238-250. | 6.1 | 525 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 2011, 43, 60-68. | 1.5 | 506 |
| 20 | Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186. | 2.9 | 490 |
| 21 | Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. Circulation, 2004, 110, 2809-2816. | 1.6 | 489 |
| 22 | Rolofylline, an Adenosine A<sub>1</sub>â^'Receptor Antagonist, in Acute Heart Failure. New England Journal of Medicine, 2010, 363, 1419-1428. | 13.9 | 473 |
| 23 | Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal, 2013, 34, 1424-1431. | 1.0 | 451 |
| 24 | Galectinâ€3: a novel mediator of heart failure development and progression. European Journal of Heart Failure, 2009, 11, 811-817. | 2.9 | 434 |
| 25 | Noncardiac Comorbidities in HeartÂFailureÂWith Reduced Versus PreservedÂEjection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293. | 1.2 | 424 |
| 26 | Treating oxidative stress in heart failure: past, present and future. European Journal of Heart Failure, 2019, 21, 425-435. | 2.9 | 407 |
| 27 | Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c. | 1.0 | 406 |
| 28 | Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. Journal of the American College of Cardiology, 2013, 61, 196-206. | 1.2 | 397 |
| 29 | Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. European Journal of Heart Failure, 2007, 9, 872-878. | 2.9 | 393 |
| 30 | Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, The, 2009, 373, 1429-1439. | 6.3 | 387 |
| 31 | Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of reninâ€“angiotensinâ€“aldosterone inhibitors. European Heart Journal, 2020, 41, 1810-1817. | 1.0 | 381 |
| 32 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116. | 13.9 | 381 |
| 33 | Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet, The, 2016, 387, 1178-1186. | 6.3 | 373 |
| 34 | Coâ€morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European Journal of Heart Failure, 2014, 16, 103-111. | 2.9 | 355 |
| 35 | B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2013, 61, 1498-1506. | 1.2 | 352 |
| 36 | Risk stratification for sudden cardiac death: current status and challenges for the future. European Heart Journal, 2014, 35, 1642-1651. | 1.0 | 341 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574. | 15.2 | 341 |
| 38 | EURObservational Research Programme: The Heart Failure Pilot Survey (ESCâ€HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084. | 2.9 | 340 |
| 39 | Heart Failure With Preserved EjectionÂFraction andÂAtrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228. | 1.2 | 292 |
| 40 | Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation, 2017, 136, 1374-1383. | 1.6 | 289 |
| 41 | Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction. Circulation, 2006, 114, 1572-1580. | 1.6 | 277 |
| 42 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293. | 1.0 | 276 |
| 43 | Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal, 2015, 36, 2565-2573. | 1.0 | 274 |
| 44 | A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114. | 1.0 | 274 |
| 45 | Randomized, doubleâ€blind, placeboâ€controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPAâ€RESPONSEâ€AHF). European Journal of Heart Failure, 2020, 22, 713-722. | 2.9 | 260 |
| 46 | Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 49, 1459-1464. | 1.2 | 257 |
| 47 | Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal, 2018, 39, 2780-2792. | 1.0 | 250 |
| 48 | Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. European Journal of Heart Failure, 2016, 18, 588-598. | 2.9 | 242 |
| 49 | Factors Influencing the Predictive PowerÂofÂModels for Predicting Mortality and/or Heart Failure Hospitalization inÂPatients With Heart Failure. JACC: Heart Failure, 2014, 2, 429-436. | 1.9 | 241 |
| 50 | <scp>MicroRNAs</scp> in heart failure: from biomarker to target for therapy. European Journal of Heart Failure, 2016, 18, 457-468. | 2.9 | 235 |
| 51 | Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3042-3051. | 1.2 | 235 |
| 52 | Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. Journal of the American College of Cardiology, 2005, 46, 125-133. | 1.2 | 232 |
| 53 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, The, 2016, 388, 2895-2903. | 6.3 | 229 |
| 54 | Advanced glycation endâ€products (AGEs) and heart failure: Pathophysiology and clinical implications. European Journal of Heart Failure, 2007, 9, 1146-1155. | 2.9 | 224 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. European Heart Journal, 2007, 28, 2018-2027. | 1.0 | 210 |
| 56 | The role of the kidney in heart failure. European Heart Journal, 2012, 33, 2135-2142. | 1.0 | 209 |
| 57 | Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2016, 18, 1472-1487. | 2.9 | 200 |
| 58 | Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090. | 1.2 | 199 |
| 59 | C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal, 2009, 30, 1187-1194. | 1.0 | 198 |
| 60 | Diuretic response in acute heart failureâ€"pathophysiology, evaluation, and therapy. Nature Reviews Cardiology, 2015, 12, 184-192. | 6.1 | 198 |
| 61 | Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1096-1103. | 2.9 | 194 |
| 62 | How to diagnose heart failure with preserved ejection fraction: the HFAâ€"PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412. | 2.9 | 193 |
| 63 | Sexâ€specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 535-542. | 2.9 | 184 |
| 64 | Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure, 2017, 19, 627-634. | 2.9 | 183 |
| 65 | Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094. | 2.9 | 182 |
| 66 | Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. European Journal of Heart Failure, 2008, 10, 997-1000. | 2.9 | 181 |
| 67 | Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 2010, 96, 1297-1302. | 1.2 | 179 |
| 68 | Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. Journal of the American College of Cardiology, 2004, 44, 63-67. | 1.2 | 178 |
| 69 | Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2017, 10, . | 1.6 | 178 |
| 70 | A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. Cardiovascular Drugs and Therapy, 2006, 20, 135-141. | 1.3 | 176 |
| 71 | Clinical outcome of renal tubular damage in chronic heart failureâ€. European Heart Journal, 2011, 32, 2705-2712. | 1.0 | 174 |
| 72 | Effects of Serelaxin in Patients with Acute Heart Failure. New England Journal of Medicine, 2019, 381, 716-726. | 13.9 | 174 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 965-973. | 2.9 | 172 |
| 74 | Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 1512. | 3.8 | 170 |
| 75 | Protective Effects of Erythropoietin in Cardiac Ischemia. Journal of the American College of Cardiology, 2006, 48, 2161-2167. | 1.2 | 167 |
| 76 | Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423. | 2.9 | 162 |
| 77 | The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1973-1981. | 1.2 | 159 |
| 78 | Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263. | 6.3 | 159 |
| 79 | Both inâ€and outâ€hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). European Journal of Heart Failure, 2009, 11, 847-854. | 2.9 | 157 |
| 80 | Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191. | 0.8 | 157 |
| 81 | Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <scp>EDIFY</scp> randomized placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 1495-1503. | 2.9 | 154 |
| 82 | Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 510-517. | 2.9 | 153 |
| 83 | Angiotensin II Type 1 Receptor A1166C Gene Polymorphism Is Associated With an Increased Response to Angiotensin II in Human Arteries. Hypertension, 2000, 35, 717-721. | 1.3 | 149 |
| 84 | A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2016, 18, 716-726. | 2.9 | 149 |
| 85 | Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795. | 1.0 | 148 |
| 86 | Vitamin D status and outcomes in heart failure patients. European Journal of Heart Failure, 2011, 13, 619-625. | 2.9 | 147 |
| 87 | Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure, 2018, 11, e004519. | 1.6 | 147 |
| 88 | A single dose of erythropoietin in ST-elevation myocardial infarction. European Heart Journal, 2010, 31, 2593-2600. | 1.0 | 144 |
| 89 | Adrenomedullin in heart failure: pathophysiology and therapeutic application. European Journal of Heart Failure, 2019, 21, 163-171. | 2.9 | 144 |
| 90 | Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nature Reviews Cardiology, 2020, 17, 641-655. | 6.1 | 143 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the EfficacyÂand Safety of the Oral Soluble Guanylate Cyclase Stimulator. JACC: Heart Failure, 2018, 6, 96-104. | 1.9 | 141 |
| 92 | Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. European Journal of Heart Failure, 2010, 12, 974-982. | 2.9 | 140 |
| 93 | Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139. | 0.8 | 140 |
| 94 | Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1303-1311. | 2.9 | 138 |
| 95 | Erythropoietin in cardiovascular diseases. European Heart Journal, 2004, 25, 285-291. | 1.0 | 136 |
| 96 | Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). American Journal of Cardiology, 2001, 87, 542-546. | 0.7 | 135 |
| 97 | Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. European Heart Journal, 2006, 28, 166-171. | 1.0 | 134 |
| 98 | Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcomeâ€”an analysis from <scp>RELAXâ€AHF</scp>. European Journal of Heart Failure, 2014, 16, 1230-1240. | 2.9 | 134 |
| 99 | Improving risk prediction in heart failure using machine learning. European Journal of Heart Failure, 2020, 22, 139-147. | 2.9 | 132 |
| 100 | Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. Europace, 2018, 20, e1-e10. | 0.7 | 131 |
| 101 | Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 92-98. | 1.9 | 129 |
| 102 | Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. Journal of the American College of Cardiology, 2011, 57, 1899-1907. | 1.2 | 125 |
| 103 | Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure. JACC: Heart Failure, 2014, 2, 84-92. | 1.9 | 123 |
| 104 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function. Journal of the American College of Cardiology, 2011, 57, 2233-2241. | 1.2 | 121 |
| 105 | Levels of Hematopoiesis InhibitorN-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. Circulation, 2005, 112, 1743-1747. | 1.6 | 120 |
| 106 | Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. European Journal of Heart Failure, 2011, 13, 1111-1120. | 2.9 | 119 |
| 107 | Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. European Heart Journal, 2005, 26, 2588-2595. | 1.0 | 118 |
| 108 | Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Reviews, 2013, 18, 123-134. | 1.7 | 118 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. Journal of the American College of Cardiology, 2015, 65, 1668-1682. | 1.2 | 116 |
| 110 | The PROTECT inâ€hospital risk model: 7â€day outcome in patients hospitalized with acute heart failure and renal dysfunction. European Journal of Heart Failure, 2012, 14, 605-612. | 2.9 | 115 |
| 111 | A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2022, 10, 73-84. | 1.9 | 115 |
| 112 | Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Failure Reviews, 2009, 14, 321-329. | 1.7 | 113 |
| 113 | Decongestion in acute heart failure. European Journal of Heart Failure, 2014, 16, 471-482. | 2.9 | 113 |
| 114 | Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. The Lancet Global Health, 2018, 6, e1008-e1018. | 2.9 | 113 |
| 115 | Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <scp>RELAXâ€AHF</scp> study. European Journal of Heart Failure, 2015, 17, 1262-1270. | 2.9 | 110 |
| 116 | Diuretic response in acute heart failureâ€”an analysis from ASCEND-HF. American Heart Journal, 2015, 170, 313-321.e4. | 1.2 | 110 |
| 117 | The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 2108-2124. | 1.8 | 108 |
| 118 | Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 76-87. | 1.6 | 107 |
| 119 | Smoking and Cardiac Events After Venous Coronary Bypass Surgery. Circulation, 1996, 93, 42-47. | 1.6 | 107 |
| 120 | Obstetric complications in Marfan syndrome. International Journal of Cardiology, 2006, 110, 53-59. | 0.8 | 106 |
| 121 | A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. European Heart Journal, 2014, 35, 431-441. | 1.0 | 104 |
| 122 | Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAXâ€AHFâ€2 study. European Journal of Heart Failure, 2017, 19, 800-809. | 2.9 | 104 |
| 123 | N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. European Heart Journal, 2010, 31, 120-127. | 1.0 | 103 |
| 124 | The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure. European Journal of Heart Failure, 2014, 16, 86-94. | 2.9 | 102 |
| 125 | Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). European Heart Journal, 2017, 38, 2364-2373. | 1.0 | 102 |
| 126 | Differential associations between renal function and â€œmodifiableâ€•risk factors in patients with chronic heart failure. Clinical Research in Cardiology, 2009, 98, 121-129. | 1.5 | 101 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. European Journal of Heart Failure, 2011, 13, 899-908. | 2.9 | 101 |
| 128 | Troponin I in acute decompensated heart failure: insights from the ASCENDâ€HF study. European Journal of Heart Failure, 2012, 14, 1257-1264. | 2.9 | 101 |
| 129 | Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Preâ€RELAXâ€AHF. European Journal of Heart Failure, 2011, 13, 961-967. | 2.9 | 99 |
| 130 | Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, . | 1.6 | 93 |
| 131 | Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2018, 19, 425-432. | 0.5 | 93 |
| 132 | Prognostic Value of Plasma Neutrophil Gelatinaseâ€“Associated Lipocalin for Mortality in Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 35-42. | 1.6 | 92 |
| 133 | Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. European Journal of Heart Failure, 2005, 7, 81-86. | 2.9 | 90 |
| 134 | Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050. | 1.0 | 90 |
| 135 | Reninâ€“Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2017, 10, . | 1.6 | 89 |
| 136 | Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660. | 2.9 | 89 |
| 137 | Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Preâ€RELAXâ€AHF study. European Journal of Heart Failure, 2010, 12, 1130-1139. | 2.9 | 88 |
| 138 | Extracorporeal Ultrafiltration for FluidÂOverload in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2428-2445. | 1.2 | 88 |
| 139 | N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939. | 1.9 | 88 |
| 140 | Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1615-1623. | 2.2 | 87 |
| 141 | Tubular Damage and Worsening Renal Function in Chronic Heart Failure. JACC: Heart Failure, 2013, 1, 417-424. | 1.9 | 87 |
| 142 | Bone marrow dysfunction in chronic heart failure patients. European Journal of Heart Failure, 2010, 12, 676-684. | 2.9 | 86 |
| 143 | Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Advanced Chronic Heart Failure. American Journal of Cardiology, 2013, 112, 831-837. | 0.7 | 86 |
| 144 | Growth differentiation factor 15 (<scp>GDF</scp>â€15) in patients admitted for acute heart failure: results from the <scp>RELAXâ€AHF</scp> study. European Journal of Heart Failure, 2015, 17, 1133-1143. | 2.9 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal, 2009, 30, 1331-1339. | 1.0 | 85 |
| 146 | Waistâ€toâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277. | 2.9 | 85 |
| 147 | Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. European Heart Journal, 2011, 32, 1519-1534. | 1.0 | 84 |
| 148 | Body Weight Change During and AfterÂHospitalization for Acute HeartÂFailure:ÂPatient Characteristics, Markers of Congestion, and Outcomes. JACC: Heart Failure, 2017, 5, 1-13. | 1.9 | 84 |
| 149 | Selenium and outcome in heart failure. European Journal of Heart Failure, 2020, 22, 1415-1423. | 2.9 | 84 |
| 150 | The Cardiorenal Syndrome in Heart Failure. Progress in Cardiovascular Diseases, 2011, 54, 144-153. | 1.6 | 83 |
| 151 | Neurohormonal and clinical sex differences in heart failure. European Heart Journal, 2013, 34, 2538-2547. | 1.0 | 83 |
| 152 | Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. European Journal of Heart Failure, 2007, 9, 787-794. | 2.9 | 82 |
| 153 | Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. Circulation: Heart Failure, 2011, 4, 724-732. | 1.6 | 82 |
| 154 | A multimarker multiâ€time pointâ€based risk stratification strategy in acute heart failure: results from the <scp>RELAXâ€AHF</scp> trial. European Journal of Heart Failure, 2017, 19, 1001-1010. | 2.9 | 81 |
| 155 | Pregnancy in women with corrected tetralogy of Fallot: Occurrence and predictors of adverse events. American Heart Journal, 2011, 161, 307-313. | 1.2 | 80 |
| 156 | Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959. | 1.6 | 80 |
| 157 | Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, . | 1.6 | 80 |
| 158 | Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. European Journal of Heart Failure, 2017, 19, 1014-1022. | 2.9 | 80 |
| 159 | Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 68-78. | 2.9 | 79 |
| 160 | Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2017, 19, 1284-1293. | 2.9 | 79 |
| 161 | Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1177-1183. | 1.2 | 78 |
| 162 | Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3442-3451. | 1.0 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517. | 1.9 | 78 |
| 164 | Low Recurrence of Angina Pectoris After Coronary Artery Bypass Graft Surgery With Bilateral Internal Thoracic and Right Gastroepiploic Arteries. Circulation, 1998, 97, 2402-2405. | 1.6 | 76 |
| 165 | Clinical and prognostic value of advanced glycation end-products in chronic heart failure. European Heart Journal, 2007, 28, 2879-2885. | 1.0 | 76 |
| 166 | Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure, 2015, 17, 224-232. | 2.9 | 74 |
| 167 | Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489. | 2.9 | 74 |
| 168 | Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413. | 1.2 | 74 |
| 169 | Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. European Heart Journal, 2008, 29, 1510-1515. | 1.0 | 72 |
| 170 | Lowâ€dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. European Journal of Heart Failure, 2008, 10, 22-29. | 2.9 | 72 |
| 171 | Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovascular Research, 2010, 87, 30-39. | 1.8 | 72 |
| 172 | Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. European Heart Journal, 2005, 26, 1759-1764. | 1.0 | 71 |
| 173 | The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 282-289. | 1.2 | 71 |
| 174 | International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better shortâ€term outcomes in patients enrolled in Eastern Europe and Russia in the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2014, 16, 614-624. | 2.9 | 71 |
| 175 | Hemoglobin levels and 30-day mortality in patients after myocardial infarction. International Journal of Cardiology, 2005, 100, 289-292. | 0.8 | 70 |
| 176 | Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. European Journal of Heart Failure, 2016, 18, 830-839. | 2.9 | 70 |
| 177 | Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 983-991. | 2.9 | 70 |
| 178 | Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. European Heart Journal, 2005, 26, 2581-2587. | 1.0 | 69 |
| 179 | Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280. | 2.9 | 69 |
| 180 | Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3029-3039. | 1.2 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal, 2019, 40, 3616-3625. | 1.0 | 69 |
| 182 | Heart Failure Therapeutics on theÂBasisÂofÂaÂBiased Ligand of theÂAngiotensin-2 TypeÂ1ÂReceptor. JACC: Heart Failure, 2015, 3, 193-201. | 1.9 | 68 |
| 183 | Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics, 2018, 8, 4155-4169. | 4.6 | 68 |
| 184 | Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886. | 2.9 | 68 |
| 185 | Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. European Journal of Heart Failure, 2011, 13, 76-82. | 2.9 | 67 |
| 186 | Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <scp>LCZ696</scp>, in patients with heart failure with preserved ejection fraction: an analysis of the <scp>PARAMOUNT</scp> trial. European Journal of Heart Failure, 2014, 16, 671-677. | 2.9 | 67 |
| 187 | What have we learned about heart failure with midâ€range ejection fraction one year after its introduction?. European Journal of Heart Failure, 2017, 19, 1569-1573. | 2.9 | 67 |
| 188 | Sodiumâ€“glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441. | 2.9 | 67 |
| 189 | Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clinical Research in Cardiology, 2017, 106, 598-609. | 1.5 | 66 |
| 190 | Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. Journal of Cardiac Failure, 2018, 24, 177-185. | 0.7 | 65 |
| 191 | Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 2.9 | 65 |
| 192 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117. | 1.0 | 65 |
| 193 | Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288. | 1.6 | 65 |
| 194 | Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. PLoS Medicine, 2019, 16, e1002916. | 3.9 | 64 |
| 195 | Bioâ€adrenomedullin as a marker of congestion in patients with newâ€onset and worsening heart failure. European Journal of Heart Failure, 2019, 21, 732-743. | 2.9 | 64 |
| 196 | Dual pathway for angiotensin II formation in human internal mammary arteries. British Journal of Pharmacology, 1998, 125, 1028-1032. | 2.7 | 62 |
| 197 | Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal, 2014, 35, 42-47. | 1.0 | 61 |
| 198 | Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 | 0.7 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 457-462. | 1.6 | 60 |
| 200 | Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 59-67. | 1.6 | 60 |
| 201 | Sexâ€specific associations of obesity and Nâ€terminal proâ€Bâ€type natriuretic peptide levels in the general population. European Journal of Heart Failure, 2018, 20, 1205-1214. | 2.9 | 60 |
| 202 | Sodiumâ€“glucose coâ€transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial. European Journal of Heart Failure, 2021, 23, 826-834. | 2.9 | 60 |
| 203 | Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60â€day outcomes in the PROTECT pilot study. European Journal of Heart Failure, 2010, 12, 499-507. | 2.9 | 59 |
| 204 | The additive burden of iron deficiency in the cardiorenalâ€“anaemia axis: scope of a problem and its consequences. European Journal of Heart Failure, 2014, 16, 655-662. | 2.9 | 59 |
| 205 | The cardiopulmonary continuum systemic inflammation as â€˜common soilâ€™ of heart and lung disease. International Journal of Cardiology, 2010, 145, 172-176. | 0.8 | 58 |
| 206 | Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. Circulation: Heart Failure, 2018, 11, e004644. | 1.6 | 58 |
| 207 | CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. American Journal of Medicine, 2020, 133, 370-380.e4. | 0.6 | 58 |
| 208 | Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> (<scp>Vericiguat</scp> Global Study in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 3.9 | 58 |
| 209 | High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2014, 20, 319-326. | 0.7 | 57 |
| 210 | Potassium and the use of reninâ€“angiotensinâ€“aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€CHF. European Journal of Heart Failure, 2018, 20, 923-930. | 2.9 | 57 |
| 211 | Clinical Role of CA125 in WorseningÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 386-397. | 1.9 | 57 |
| 212 | Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation, 2022, 145, 693-712. | 1.6 | 57 |
| 213 | Endogenous Erythropoietin and Outcome in Heart Failure. Circulation, 2010, 121, 245-251. | 1.6 | 56 |
| 214 | Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. European Heart Journal, 2013, 34, 3128-3136. | 1.0 | 56 |
| 215 | Effect of Serelaxin on Mode of Death inÂAcute Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1591-1598. | 1.2 | 56 |
| 216 | Exclusive use of arterial grafts in coronary artery bypass operations for three-vessel disease: Use of both thoracic arteries and the gastroepiploic artery in 256 consecutive patients. Journal of Thoracic and Cardiovascular Surgery, 1996, 112, 935-942. | 0.4 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | The VEGF +405 CC Promoter Polymorphism is Associated With an Impaired Prognosis in Patients With Chronic Heart Failure: A MERIT-HF Substudy. Journal of Cardiac Failure, 2005, 11, 279-284. | 0.7 | 55 |
| 218 | Biomarkers and low risk in heart failure. Data from <scp>COACH</scp> and <scp>TRIUMPH</scp>. European Journal of Heart Failure, 2015, 17, 1271-1282. | 2.9 | 55 |
| 219 | Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Failure Reviews, 2016, 21, 95-102. | 1.7 | 55 |
| 220 | Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90. | 0.8 | 55 |
| 221 | Clinical importance of urinary sodium excretion in acute heart failure. European Journal of Heart Failure, 2020, 22, 1438-1447. | 2.9 | 55 |
| 222 | Iron deficiency and red cell indices in patients with heart failure. European Journal of Heart Failure, 2018, 20, 114-122. | 2.9 | 54 |
| 223 | Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239. | 0.8 | 53 |
| 224 | A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320. | 2.9 | 53 |
| 225 | Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). American Heart Journal, 2008, 155, 817-822. | 1.2 | 52 |
| 226 | Vasodilators in the treatment of acute heart failure: what we know, what we donâ€™t. Heart Failure Reviews, 2009, 14, 299-307. | 1.7 | 52 |
| 227 | Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. Cardiovascular Drugs and Therapy, 2008, 22, 265-274. | 1.3 | 51 |
| 228 | Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic KidneyÂDisease. JACC: Heart Failure, 2019, 7, 25-32. | 1.9 | 51 |
| 229 | Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. Journal of the American Heart Association, 2021, 10, e018549. | 1.6 | 51 |
| 230 | Telomere length and psychological well-being in patients with chronic heart failure. Age and Ageing, 2010, 39, 223-227. | 0.7 | 50 |
| 231 | Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opinion on Investigational Drugs, 2015, 24, 1123-1135. | 1.9 | 50 |
| 232 | Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and healthâ€related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2017, 19, 116-125. | 2.9 | 50 |
| 233 | Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. European Journal of Heart Failure, 2020, 22, 1147-1155. | 2.9 | 50 |
| 234 | The (pro)renin receptor in health and disease. Annals of Medicine, 2010, 42, 13-18. | 1.5 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Sexâ€specific acute heart failure phenotypes and outcomes from PROTECT. European Journal of Heart Failure, 2013, 15, 1374-1381. | 2.9 | 49 |
| 236 | Use of High-Sensitivity Troponin T to IdentifyÂPatients With Acute Heart Failure atÂLowerÂRisk for Adverse Outcomes. JACC: Heart Failure, 2016, 4, 591-599. | 1.9 | 49 |
| 237 | Patient journey after admission for acute heart failure: length of stay, 30â€day readmission and 90â€day mortality. European Journal of Heart Failure, 2016, 18, 1041-1050. | 2.9 | 49 |
| 238 | Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. European Journal of Heart Failure, 2020, 22, 1649-1658. | 2.9 | 49 |
| 239 | High Prevalence of Microalbuminuria in Chronic Heart Failure Patients. Journal of Cardiac Failure, 2005, 11, 602-606. | 0.7 | 48 |
| 240 | Co-morbidities in heart failure. Heart Failure Reviews, 2014, 19, 163-172. | 1.7 | 48 |
| 241 | Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <scp>PROTECT</scp> trial. European Journal of Heart Failure, 2015, 17, 109-118. | 2.9 | 48 |
| 242 | Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. European Journal of Heart Failure, 2018, 20, 89-96. | 2.9 | 48 |
| 243 | Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2005, 129, 330-335. | 0.4 | 47 |
| 244 | Increased mortality with elevated plasma endothelinâ€1 in acute heart failure: an ASCENDâ€HF biomarker substudy. European Journal of Heart Failure, 2016, 18, 290-297. | 2.9 | 47 |
| 245 | Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411. | 0.7 | 47 |
| 246 | Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875. | 1.0 | 47 |
| 247 | Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 321, 2101. | 3.8 | 47 |
| 248 | Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171. | 2.9 | 47 |
| 249 | The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364. | 1.0 | 47 |
| 250 | Effects of oral appliances and CPAP on the left ventricle and natriuretic peptides. International Journal of Cardiology, 2008, 128, 232-239. | 0.8 | 46 |
| 251 | High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. European Journal of Heart Failure, 2021, 23, 919-932. | 2.9 | 46 |
| 252 | Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. Journal of Cardiac Failure, 2020, 26, 429-437. | 0.7 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Prognostic Value of Baseline and ChangesÂin Circulating Soluble ST2 LevelsÂand the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure, 2016, 4, 68-77. | 1.9 | 45 |
| 254 | Comorbidities in Heart Failure. Handbook of Experimental Pharmacology, 2017, 243, 35-66. | 0.9 | 45 |
| 255 | Epicardial Adipose Tissue and Invasive Hemodynamics in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 667-676. | 1.9 | 45 |
| 256 | Statins in the Treatment of Chronic Heart Failure: A Systematic Review. PLoS Medicine, 2006, 3, e333. | 3.9 | 44 |
| 257 | Statins in the treatment of chronic heart failure: Biological and clinical considerations. Cardiovascular Research, 2006, 71, 443-454. | 1.8 | 44 |
| 258 | Possible Association Between Telomere Length and Renal Dysfunction in Patients With Chronic Heart Failure. American Journal of Cardiology, 2008, 102, 207-210. | 0.7 | 44 |
| 259 | Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Failure Reviews, 2014, 19, 369-381. | 1.7 | 44 |
| 260 | Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403. | 1.9 | 44 |
| 261 | Heart failure in the outpatient versus inpatient setting: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 112-120. | 2.9 | 44 |
| 262 | Renal Compression in HeartÂFailure. JACC: Heart Failure, 2022, 10, 175-183. | 1.9 | 44 |
| 263 | Skin-Autofluorescence, a Measure of Tissue Advanced Glycation End-Products (AGEs), is Related to Diastolic Function in Dialysis Patients. Journal of Cardiac Failure, 2008, 14, 596-602. | 0.7 | 43 |
| 264 | Hemoconcentration-guided Diuresis in HeartÂFailure. American Journal of Medicine, 2014, 127, 1154-1159. | 0.6 | 43 |
| 265 | The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136. | 1.2 | 43 |
| 266 | Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. JAMA Cardiology, 2019, 4, 696. | 3.0 | 43 |
| 267 | Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. American Journal of Cardiology, 2004, 94, 240-243. | 0.7 | 42 |
| 268 | Effects of alagebrium, an advanced glycation endâ€product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. European Journal of Heart Failure, 2010, 12, 294-300. | 2.9 | 42 |
| 269 | Prognostic value of Nâ€terminal pro Câ€type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. European Journal of Heart Failure, 2014, 16, 958-966. | 2.9 | 42 |
| 270 | The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <scp>SHIFT</scp>. European Journal of Heart Failure, 2014, 16, 426-434. | 2.9 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. International Journal of Cardiology, 2017, 243, 360-366. | 0.8 | 42 |
| 272 | Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular endâ€diastolic pressure. European Journal of Heart Failure, 2017, 19, 1483-1490. | 2.9 | 42 |
| 273 | Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 304-314. | 2.9 | 42 |
| 274 | Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965. | 1.6 | 41 |
| 275 | The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. Drug Safety, 2012, 35, 233-244. | 1.4 | 40 |
| 276 | The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. JACC: Heart Failure, 2013, 1, 164-169. | 1.9 | 40 |
| 277 | IGFBP7 (Insulin-Like Growth Factorâ€"Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circulation: Heart Failure, 2018, 11, e005133. | 1.6 | 40 |
| 278 | Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure. Circulation, 2020, 141, 1915-1926. | 1.6 | 40 |
| 279 | Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 560-571. | 0.8 | 40 |
| 280 | Effect of Intensive Versus Moderate Lipid Lowering on Endothelial Function and Vascular Responsiveness to Angiotensin II in Stable Coronary Artery Disease. American Journal of Cardiology, 2005, 96, 1361-1364. | 0.7 | 39 |
| 281 | Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure, 2008, 10, 201-213. | 2.9 | 39 |
| 282 | Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure. Circulation, 2009, 120, 35-41. | 1.6 | 39 |
| 283 | Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq1 1 0.784314 rgBT /Overlock | 0.7 | 39 |
| 284 | Advanced Glycation Endproducts in Chronic Heart Failure. Annals of the New York Academy of Sciences, 2008, 1126, 225-230. | 1.8 | 38 |
| 285 | Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Failure Reviews, 2012, 17, 221-228. | 1.7 | 38 |
| 286 | Current and novel renal biomarkers in heart failure. Heart Failure Reviews, 2012, 17, 241-250. | 1.7 | 38 |
| 287 | Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failureâ€"Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. Journal of Cardiac Failure, 2014, 20, 407-413. | 0.7 | 38 |
| 288 | Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. PLoS ONE, 2015, 10, e0125215. | 1.1 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | 2016 ESC and ACC/AHA/HFSA heart failure guideline update â€" what is new and why is it important?. Nature Reviews Cardiology, 2016, 13, 623-628. | 6.1 | 38 |
| 290 | Serum ferritin and risk for newâ€onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017, 19, 348-356. | 2.9 | 38 |
| 291 | OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovascular Research, 2018, 114, 1871-1882. | 1.8 | 38 |
| 292 | Telomere length and outcome in heart failure. Annals of Medicine, 2010, 42, 36-44. | 1.5 | 37 |
| 293 | Depressive symptoms and inflammation in patients hospitalized for heart failure. American Heart Journal, 2011, 161, 1053-1059. | 1.2 | 37 |
| 294 | Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opinion on Investigational Drugs, 2016, 25, 117-127. | 1.9 | 37 |
| 295 | Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure. Circulation: Heart Failure, 2020, 13, e006731. | 1.6 | 37 |
| 296 | Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2014, 7, 994-1002. | 1.6 | 36 |
| 297 | The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCENDâ€HF. European Journal of Heart Failure, 2016, 18, 306-313. | 2.9 | 36 |
| 298 | Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, . | 5.8 | 36 |
| 299 | Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. American Journal of Hypertension, 2005, 18, 342-347. | 1.0 | 35 |
| 300 | Diabetes: a driver for heart failure. Heart, 2011, 97, 774-780. | 1.2 | 35 |
| 301 | Comparative Assessment of Short-TermÂAdverse Events in Acute Heart Failure WithÂCystatin C andÂOther Estimates ofÂRenal Function. JACC: Heart Failure, 2015, 3, 40-49. | 1.9 | 35 |
| 302 | Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, . | 1.6 | 35 |
| 303 | MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569. | 0.8 | 35 |
| 304 | Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 386-398. | 1.2 | 35 |
| 305 | Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> trial. European Journal of Heart Failure, 2021, 23, 1300-1312. | 2.9 | 35 |
| 306 | Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. Clinical Research in Cardiology, 2014, 103, 976-983. | 1.5 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 2016, 204, 164-171. | 0.8 | 34 |
| 308 | Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738. | 2.9 | 34 |
| 309 | Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO 2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. Journal of Cardiac Failure, 2017, 23, 777-782. | 0.7 | 34 |
| 310 | Safety, Tolerability and efficacy of Rapid Optimization, helped by NTâ€proBNP and GDFâ€15, of Heart Failure therapies (STRONGâ€HF): rationale and design for a multicentre, randomized, parallelâ€group study. European Journal of Heart Failure, 2019, 21, 1459-1467. | 2.9 | 34 |
| 311 | Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 2022, 24, 365-374. | 2.9 | 34 |
| 312 | Rationale and Design of the VITALITY-HFpEF Trial. Circulation: Heart Failure, 2019, 12, e005998. | 1.6 | 33 |
| 313 | Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 2020, 22, 683-691. | 2.9 | 33 |
| 314 | Neutrophilâ€toâ€lymphocyte ratio and outcomes in patients with newâ€onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, 8, 3168-3179. | 1.4 | 33 |
| 315 | Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464. | 1.0 | 33 |
| 316 | Nebivolol: third-generation Î²-blockade. Expert Opinion on Pharmacotherapy, 2007, 8, 1539-1550. | 0.9 | 32 |
| 317 | Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. International Journal of Cardiology, 2013, 166, 729-735. | 0.8 | 32 |
| 318 | Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649. | 2.9 | 32 |
| 319 | A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153. | 1.5 | 32 |
| 320 | Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072. | 2.0 | 32 |
| 321 | Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2021, 23, 1750-1758. | 2.9 | 32 |
| 322 | Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 2361-2367. | 1.0 | 31 |
| 323 | Urinary Proteins in Heart Failure. Progress in Cardiovascular Diseases, 2012, 55, 44-55. | 1.6 | 31 |
| 324 | Hemodialysis-Induced Regional Left Ventricular Systolic Dysfunction and Inflammation: A Cross-sectional Study. American Journal of Kidney Diseases, 2014, 64, 265-273. | 2.1 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Bioâ€adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. European Journal of Heart Failure, 2018, 20, 1363-1365. | 2.9 | 31 |
| 326 | Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. European Heart Journal, 2020, 41, 2353-2355. | 1.0 | 31 |
| 327 | Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology, 2017, 106, 802-812. | 1.5 | 30 |
| 328 | Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239. | 0.7 | 30 |
| 329 | Proteomic diversity of highâ€density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267. | 2.9 | 30 |
| 330 | Dynamics of cerebral blood flow in patients with mild nonâ€ischaemic heart failure. European Journal of Heart Failure, 2017, 19, 261-268. | 2.9 | 29 |
| 331 | Sudden cardiac death after acute heart failure hospital admission: insights from ASCENDâ€HF. European Journal of Heart Failure, 2018, 20, 525-532. | 2.9 | 29 |
| 332 | Î²<sub>1</sub>-Adrenoreceptor Autoantibodies in Heart Failure. Circulation: Heart Failure, 2020, 13, e006155. | 1.6 | 29 |
| 333 | The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 2020, 109, 331-338. | 1.5 | 28 |
| 334 | Plasma proteomic approach in patients withÂheart failure: insights into pathogenesis ofÂdisease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80. | 2.9 | 28 |
| 335 | A network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâ€ischaemic heart failure. European Journal of Heart Failure, 2020, 22, 821-833. | 2.9 | 28 |
| 336 | Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis. Journal of the American College of Cardiology, 2000, 36, 2047-2053. | 1.2 | 27 |
| 337 | Long-term tricuspid valve prosthesis-related complications in patients with congenital heart disease. European Journal of Cardio-thoracic Surgery, 2014, 45, 83-89. | 0.6 | 27 |
| 338 | Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1â€receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610. | 2.9 | 27 |
| 339 | Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, doubleâ€blind, placeboâ€controlled trial. European Journal of Heart Failure, 2019, 21, 1426-1433. | 2.9 | 27 |
| 340 | The burden of nonâ€cardiac comorbidities and association with clinical outcomes in an acute heart failure trialÂâ€“Âinsights from ASCENDâ€HF. European Journal of Heart Failure, 2020, 22, 1022-1031. | 2.9 | 27 |
| 341 | Long-term results after successful percutaneous transluminal coronary angioplasty in patients over 75 years of age. American Journal of Cardiology, 1996, 77, 690-695. | 0.7 | 26 |
| 342 | Vitamin B12and folate deficiency in chronic heart failure. Heart, 2015, 101, 302-310. | 1.2 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Ove | 0.7 | 26 |
| 344 | Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. Journal of Cardiac Failure, 2017, 23, 2-9. | 0.7 | 26 |
| 345 | Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. European Heart Journal, 2018, 39, 2793-2799. | 1.0 | 26 |
| 346 | Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979. | 1.9 | 26 |
| 347 | Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. European Journal of Heart Failure, 2021, 23, 567-577. | 2.9 | 26 |
| 348 | Natriuresisâ€guided therapy in acute heart failure: rationale and design of the <scp>Pragmatic Urinary Sodiumâ€based treatment algoritHm</scp> in <scp>Acute Heart Failure</scp> (<scp>PUSHâ€AHF</scp>) trial. European Journal of Heart Failure, 2022, 24, 385-392. | 2.9 | 26 |
| 349 | Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 1346-1356. | 2.9 | 26 |
| 350 | Anemia in chronic heart failure: etiology and treatment options. Current Opinion in Cardiology, 2008, 23, 141-147. | 0.8 | 25 |
| 351 | Low pulse pressure is an independent predictor of mortality and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients. International Journal of Cardiology, 2009, 131, 336-344. | 0.8 | 25 |
| 352 | Geographical location affects the levels and association of trimethylamine Nâ€oxide with heart failure mortality in BIOSTATâ€CHF: a postâ€hoc analysis. European Journal of Heart Failure, 2019, 21, 1291-1294. | 2.9 | 25 |
| 353 | Clinical correlates and outcome associated with changes in 6â€minute walking distance in patients with heart failure: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 218-226. | 2.9 | 25 |
| 354 | Distinct Pathological Pathways in Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2020, 8, 234-242. | 1.9 | 25 |
| 355 | Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. PLoS ONE, 2017, 12, e0177242. | 1.1 | 25 |
| 356 | Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 2015, 17, 697-706. | 2.9 | 24 |
| 357 | Partial Adenosine A1 Agonist in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 177-203. | 0.9 | 24 |
| 358 | Effects of serelaxin in patients admitted for acute heart failure: a metaâ€analysis. European Journal of Heart Failure, 2020, 22, 315-329. | 2.9 | 24 |
| 359 | The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. European Journal of Heart Failure, 2020, 22, 2102-2111. | 2.9 | 24 |
| 360 | Effects of combined reninâ€“angiotensinâ€“aldosterone system inhibitor and betaâ€blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTATâ€CHF</scp> and <scp>ASIANâ€HF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482. | 2.9 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. Circulation: Heart Failure, 2021, 14, e007871. | 1.6 | 24 |
| 362 | Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. Cardiovascular Drugs and Therapy, 2000, 14, 55-60. | 1.3 | 23 |
| 363 | The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opinion on Investigational Drugs, 2013, 22, 1041-1047. | 1.9 | 23 |
| 364 | Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology, 2015, 11, 585-595. | 0.5 | 23 |
| 365 | Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. Lancet, The, 2015, 385, S26. | 6.3 | 23 |
| 366 | Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. Circulation: Heart Failure, 2019, 12, e005544. | 1.6 | 23 |
| 367 | Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction. Circulation, 1997, 95, 2607-2609. | 1.6 | 23 |
| 368 | Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <scp>ASCENDâ€HF</scp>. European Journal of Heart Failure, 2015, 17, 340-346. | 2.9 | 22 |
| 369 | Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCENDâ€HF. Clinical Cardiology, 2018, 41, 945-952. | 0.7 | 22 |
| 370 | Hepatorenal dysfunction identifies highâ€risk patients with acute heart failure: insights from the RELAXâ€AHF trial. ESC Heart Failure, 2019, 6, 1188-1198. | 1.4 | 22 |
| 371 | Chloride in HeartÂFailure. JACC: Heart Failure, 2021, 9, 904-915. | 1.9 | 22 |
| 372 | Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. International Journal of Cardiology, 2006, 108, 63-67. | 0.8 | 21 |
| 373 | Advanced glycation endâ€products, antiâ€hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction. European Journal of Heart Failure, 2010, 12, 397-403. | 2.9 | 21 |
| 374 | A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine. Canadian Journal of Cardiology, 2014, 30, 288-295. | 0.8 | 21 |
| 375 | Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€AHFâ€2 trial. European Journal of Heart Failure, 2020, 22, 726-738. | 2.9 | 21 |
| 376 | Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499. | 1.6 | 21 |
| 377 | Vascular Function and Mild Renal Impairment in Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 379-384. | 1.1 | 20 |
| 378 | Functional and Hemodynamic Cardiac Determinants of Exercise Capacity in Patients With Systolic Heart Failure. American Journal of Cardiology, 2012, 110, 1336-1341. | 0.7 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Changes in Left Ventricular Diastolic Function During Hemodialysis Sessions. American Journal of Kidney Diseases, 2013, 62, 549-556. | 2.1 | 20 |
| 380 | Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 1022-1031. | 2.9 | 20 |
| 381 | Heart failure treatment upâ€titration and outcome and age: an analysis of BIOSTATâ€CHF. European Journal of Heart Failure, 2021, 23, 436-444. | 2.9 | 20 |
| 382 | Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2020, 109, 1048-1059. | 1.5 | 20 |
| 383 | Additional burden of iron deficiency in heart failure patients beyond the cardioâ€renal anaemia syndrome: findings from the <scp>BIOSTATâ€CHF</scp> study. European Journal of Heart Failure, 2022, 24, 192-204. | 2.9 | 20 |
| 384 | Usefulness of Preoperative C-Reactive Protein and Soluble Intercellular Adhesion Molecule-1 Level for Predicting Future Cardiovascular Events After Coronary Artery Bypass Grafting. American Journal of Cardiology, 2006, 97, 1697-1701. | 0.7 | 19 |
| 385 | Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. European Journal of Heart Failure, 2010, 12, 348-353. | 2.9 | 19 |
| 386 | Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 777-785. | 1.9 | 19 |
| 387 | Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€CHF. European Journal of Heart Failure, 2021, 23, 43-57. | 2.9 | 19 |
| 388 | Spironolactone in Patients With HeartÂFailure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221. | 1.2 | 19 |
| 389 | Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis. Journal of Cardiovascular Pharmacology, 2005, 45, 88-98. | 0.8 | 18 |
| 390 | Effect of Withdrawal of Pravastatin Therapy on C-Reactive Protein and Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2007, 100, 1548-1551. | 0.7 | 18 |
| 391 | Renal Function Dependent Association of AGTR1 Polymorphism (A1166C) and Electrocardiographic Left-Ventricular Hypertrophy. American Journal of Hypertension, 2007, 20, 1097-1103. | 1.0 | 18 |
| 392 | Hemoglobin levels and new-onset heart failure in the community. American Heart Journal, 2015, 169, 94-101.e2. | 1.2 | 18 |
| 393 | Very Early Diuretic Response After Admission for Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 12-19. | 0.7 | 18 |
| 394 | Is Anemia in Chronic Heart Failure Caused by Iron Deficiency?. Journal of the American College of Cardiology, 2007, 49, 2301-2302. | 1.2 | 17 |
| 395 | Ischemic patterns assessed by positron emission tomography predict adverse outcome in patients with idiopathic dilated cardiomyopathy. Journal of Nuclear Cardiology, 2009, 16, 769-774. | 1.4 | 17 |
| 396 | Why do drugs for acute heart failure fail?. European Journal of Heart Failure, 2012, 14, 955-956. | 2.9 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clinical Research in Cardiology, 2016, 105, 10-16. | 1.5 | 17 |
| 398 | Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. Clinical Research in Cardiology, 2017, 106, 280-292. | 1.5 | 17 |
| 399 | Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. Journal of Cardiac Failure, 2021, 27, 233-241. | 0.7 | 17 |
| 400 | Effects of a Novel Nitroxyl Donor in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 146-157. | 1.9 | 17 |
| 401 | Predictors of Angiotensin-Converting Enzyme Inhibitorâ€"Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients. Hypertension, 2006, 48, 870-876. | 1.3 | 16 |
| 402 | Predictive value of tissue Doppler imaging for left ventricular ejection fraction, remodelling, and infarct size after percutaneous coronary intervention for acute myocardial infarction. European Journal of Echocardiography, 2010, 11, 596-601. | 2.3 | 16 |
| 403 | Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Heart Journal, 2015, 169, 693-701.e3. | 1.2 | 16 |
| 404 | Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis. Nephrology Dialysis Transplantation, 2016, 31, 1494-1501. | 0.4 | 16 |
| 405 | Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clinical Research in Cardiology, 2016, 105, 727-737. | 1.5 | 16 |
| 406 | Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart, 2018, 104, 606-613. | 1.2 | 16 |
| 407 | Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). American Journal of Cardiology, 2018, 122, 1506-1512. | 0.7 | 16 |
| 408 | Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874. | 0.7 | 16 |
| 409 | Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration. Circulation, 2020, 142, 1117-1119. | 1.6 | 16 |
| 410 | A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. Nutrients, 2020, 12, 2541. | 1.7 | 16 |
| 411 | Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. Journal of Cardiac Failure, 2021, 27, 670-676. | 0.7 | 16 |
| 412 | Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 130-134. | 1.0 | 15 |
| 413 | Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting. Hypertension, 2004, 44, 930-934. | 1.3 | 15 |
| 414 | Ventricular dysfunction in a family with long QT syndrome type 3. Europace, 2013, 15, 1516-1521. | 0.7 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. Circulation: Heart Failure, 2016, 9, . | 1.6 | 15 |
| 416 | Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527. | 2.9 | 15 |
| 417 | Cardiovascular and nonâ€cardiovascular death distinction: the utility of troponin beyond Nâ€terminal proâ€Bâ€type natriuretic peptide. Findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2020, 22, 81-89. | 2.9 | 15 |
| 418 | Men more vulnerable to COVID-19: explained by ACE2 on the X chromosome?. European Heart Journal, 2020, 41, 3096-3096. | 1.0 | 15 |
| 419 | The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567. | 2.9 | 15 |
| 420 | Nonâ€adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatographyâ€tandem mass spectrometry (results of a prospective) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 537 | 2.9 | 15 |
| 421 | Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. Cardiovascular Research, 1997, 34, 568-574. | 1.8 | 14 |
| 422 | Progression of atherosclerosis after venous coronary artery bypass graft surgery: A 15-year follow-up study. , 1997, 41, 141-150. | | 14 |
| 423 | Î²-Adrenoceptor Antagonists in Elderly Patients with Heart Failure. Drugs and Aging, 2007, 24, 1031-1044. | 1.3 | 14 |
| 424 | HFpEF vs. HFrEF: can microRNAs advance the diagnosis?. European Journal of Heart Failure, 2015, 17, 351-354. | 2.9 | 14 |
| 425 | Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 121, 621-627. | 0.7 | 14 |
| 426 | Pregnancy After Biventricular Repair for Pulmonary Atresia With Ventricular Septal Defect. American Journal of Cardiology, 2006, 98, 262-266. | 0.7 | 13 |
| 427 | Excellent Long-Term Clinical Outcome After Coronary Artery Bypass Surgery Using Three Pedicled Arterial Grafts in Patients With Three-Vessel Disease. Annals of Thoracic Surgery, 2008, 85, 508-512. | 0.7 | 13 |
| 428 | Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal, 2009, 157, 91-96. | 1.2 | 13 |
| 429 | Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?. European Journal of Heart Failure, 2016, 18, 113-114. | 2.9 | 13 |
| 430 | High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. European Journal of Heart Failure, 2016, 18, 814-821. | 2.9 | 13 |
| 431 | Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004783. | 0.9 | 13 |
| 432 | Haemodynamic effects of the nitroxyl donor cimlanod (<scp>BMS</scp>â€986231) in chronic heart failure: a randomized trial. European Journal of Heart Failure, 2021, 23, 1147-1155. | 2.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | Cost Effectiveness of Angiotensin Receptor Blocker Monotherapy in Patients with Hypertension in the Netherlands. American Journal of Cardiovascular Drugs, 2010, 10, 49-54. | 1.0 | 12 |
| 434 | Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2013, 27, 433-439. | 1.3 | 12 |
| 435 | Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. European Journal of Internal Medicine, 2020, 71, 62-69. | 1.0 | 12 |
| 436 | Cause of Death in Patients With AcuteÂHeartÂFailure. JACC: Heart Failure, 2020, 8, 999-1008. | 1.9 | 12 |
| 437 | The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS ONE, 2016, 11, e0168340. | 1.1 | 12 |
| 438 | Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis. Heart Failure Reviews, 2022, 27, 1933-1955. | 1.7 | 12 |
| 439 | An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the losartan intervention for endpoint reduction (LIFE) study adapted to The Netherlands. Clinical Therapeutics, 2007, 29, 963-971. | 1.1 | 11 |
| 440 | Erythropoietin in Chronic Heart Failure. Congestive Heart Failure, 2007, 13, 289-292. | 2.0 | 11 |
| 441 | Low pulse pressure as a poor-manÊ¼s indicator of a low cardiac index in patients with severe cardiac dysfunction. Journal of Cardiovascular Medicine, 2014, 15, 315-321. | 0.6 | 11 |
| 442 | Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072. | 0.8 | 11 |
| 443 | Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, . | 1.6 | 11 |
| 444 | Markers of left ventricular systolic dysfunction when left ventricular ejection fraction is normal. European Journal of Heart Failure, 2018, 20, 1636-1638. | 2.9 | 11 |
| 445 | Effect of isolated ultrafiltration and isovolemic dialysis on myocardial perfusion and left ventricular function assessed with<sup>13</sup>N-NH<sub>3</sub>positron emission tomography and echocardiography. American Journal of Physiology - Renal Physiology, 2018, 314, F445-F452. | 1.3 | 11 |
| 446 | Prognostic Implications of Changes in Amino-Terminal Proâ€“B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. Journal of Cardiac Failure, 2019, 25, 703-711. | 0.7 | 11 |
| 447 | Megaâ€trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707. | 2.9 | 11 |
| 448 | Association between upâ€titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181. | 2.9 | 11 |
| 449 | Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 2021, 23, 1677-1686. | 2.9 | 11 |
| 450 | Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review. Circulation: Heart Failure, 2021, 14, e008064. | 1.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | The genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Failure, 2021, 8, 5531-5541. | 1.4 | 11 |
| 452 | Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. Circulation: Heart Failure, 2021, 14, e008548. | 1.6 | 11 |
| 453 | The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice. Cardiovascular Drugs and Therapy, 2006, 20, 69-73. | 1.3 | 10 |
| 454 | Fertility, Pregnancy, and Delivery After Biventricular Repair for Pulmonary Atresia With an Intact Ventricular Septum. American Journal of Cardiology, 2006, 98, 259-261. | 0.7 | 10 |
| 455 | Aortic valve prosthesisâ€“patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart, 2016, 102, 107-113. | 1.2 | 10 |
| 456 | Clinical and prognostic value of spot urinary creatinine in chronic heart failureâ€”An analysis from GISSI-HF. American Heart Journal, 2017, 188, 189-195. | 1.2 | 10 |
| 457 | Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 2019, 108, 797-805. | 1.5 | 10 |
| 458 | A combined bioinformatics, experimental and clinical approach to identify novel cardiacâ€specific heart failure biomarkers: is Dickkopf â€3 ( DKK3 ) a possible candidate?. European Journal of Heart Failure, 2020, 22, 2065-2074. | 2.9 | 10 |
| 459 | Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <scp>RELAXâ€AHF</scp>â€2 study. European Journal of Heart Failure, 2021, 23, 58-67. | 2.9 | 10 |
| 460 | Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, 2022, 118, 1964-1977. | 1.8 | 10 |
| 461 | Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923. | 1.5 | 10 |
| 462 | Improving clinical trial efficiency using a machine learningâ€based risk score to enrich study populations. European Journal of Heart Failure, 2022, 24, 1418-1426. | 2.9 | 10 |
| 463 | Distinct pathophysiological pathways in women and men with heart failure. European Journal of Heart Failure, 2022, 24, 1532-1544. | 2.9 | 10 |
| 464 | Usefulness of hypertriglyceridemia in predicting myocardial infarction late after coronary artery bypass operation. American Journal of Cardiology, 1997, 79, 1350-1354. | 0.7 | 9 |
| 465 | Functional antagonism of different angiotensin II type I receptor blockers in human arteries. Cardiovascular Drugs and Therapy, 2002, 16, 311-316. | 1.3 | 9 |
| 466 | Differences Between Angiotensin-Converting Enzyme Inhibition and Angiotensin II-AT1 Antagonism on Angiotensin-Mediated Responses in Human Internal Mammary Arteries. Journal of Cardiovascular Pharmacology, 2003, 41, 178-184. | 0.8 | 9 |
| 467 | Acute Administration of Angiotensin Converting Enzyme Inhibitors in Thrombolysed Myocardial Infarction Patients Is Associated with a Decreased Incidence of Heart Failure, but an Increased Re-Infarction Risk. Cardiovascular Drugs and Therapy, 2005, 19, 119-124. | 1.3 | 9 |
| 468 | Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. Current Heart Failure Reports, 2007, 4, 127-133. | 1.3 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. Expert Review of Cardiovascular Therapy, 2015, 13, 1075-1078. | 0.6 | 9 |
| 470 | Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. American Heart Journal, 2017, 187, 62-69. | 1.2 | 9 |
| 471 | Atrial Fibrillation in Heart Failure â^—. JACC: Heart Failure, 2017, 5, 575-577. | 1.9 | 9 |
| 472 | Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. Journal of Cardiac Failure, 2018, 24, 512-519. | 0.7 | 9 |
| 473 | Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLASTâ€AHF trial. European Journal of Heart Failure, 2019, 21, 1561-1570. | 2.9 | 9 |
| 474 | Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Failure, 2020, 7, 953-963. | 1.4 | 9 |
| 475 | Dipeptidyl peptidase 3, a marker of the antagonist pathway of the reninâ€“angiotensinâ€“aldosterone system in patients with heart failure. European Journal of Heart Failure, 2021, 23, 947-953. | 2.9 | 9 |
| 476 | Impaired Highâ€Density Lipoprotein Function in Patients With Heart Failure. Journal of the American Heart Association, 2021, 10, e019123. | 1.6 | 9 |
| 477 | Postâ€transplant inotrope score is associated with clinical outcomes after adult heart transplantation. Clinical Transplantation, 2021, 35, e14347. | 0.8 | 9 |
| 478 | Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484. | 2.9 | 9 |
| 479 | Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative?. European Journal of Heart Failure, 2021, 23, 1437-1444. | 2.9 | 9 |
| 480 | Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320. | 2.9 | 9 |
| 481 | A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. Cardiovascular Drugs and Therapy, 2023, 37, 743-755. | 1.3 | 9 |
| 482 | Effects of C-Reactive Protein and Cholesterol on Responsiveness In Vitro of the Internal Thoracic Artery to Angiotensin II in Patients Having Coronary Artery Bypass Grafting. American Journal of Cardiology, 2006, 98, 751-753. | 0.7 | 8 |
| 483 | Comparison of Cardiac Positron Emission Tomography Perfusion Defects During Stress Induced by Hemodialysis Versus Adenosine. American Journal of Kidney Diseases, 2012, 59, 862-864. | 2.1 | 8 |
| 484 | Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293. | 1.3 | 8 |
| 485 | Nâ€terminal proâ€Bâ€type natriuretic peptide and prognosis in <scp>Caucasian</scp> vs. <scp>Asian</scp> patients with heart failure. ESC Heart Failure, 2018, 5, 279-287. | 1.4 | 8 |
| 486 | Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes. European Heart Journal, 2020, 41, 3099-3099. | 1.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236. | 1.8 | 8 |
| 488 | Amended <scp>STRONGâ€HF</scp> study design. European Journal of Heart Failure, 2021, 23, 1981-1982. | 2.9 | 8 |
| 489 | Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008970. | 1.6 | 8 |
| 490 | Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. European Journal of Heart Failure, 2022, 24, 2131-2139. | 2.9 | 8 |
| 491 | Tackling Early Heart Failure Deaths and Readmissions by Estimating Congestion âˆ—. JACC: Heart Failure, 2015, 3, 894-895. | 1.9 | 7 |
| 492 | Implications of serial measurements of natriuretic peptides in heart failure: insights from <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2020, 22, 1486-1490. | 2.9 | 7 |
| 493 | New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. European Heart Journal, 2020, 41, 4047-4049. | 1.0 | 7 |
| 494 | Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977. | 1.5 | 7 |
| 495 | The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811. | 0.7 | 7 |
| 496 | Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 890-903. | 1.9 | 7 |
| 497 | Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, , . | 2.9 | 7 |
| 498 | Difference in long-term prognostic value of renal function between ischemic and non-ischemic mild heart failure. International Journal of Cardiology, 2006, 107, 73-77. | 0.8 | 6 |
| 499 | The European Heart Journal and the European Journal of Heart Failure: partners in scientific publishing. European Journal of Heart Failure, 2012, 14, 1075-1082. | 2.9 | 6 |
| 500 | The puzzle of kidney dysfunction in heart failure: an introduction. Heart Failure Reviews, 2012, 17, 129-131. | 1.7 | 6 |
| 501 | Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure â€" Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975. | 0.8 | 6 |
| 502 | Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35. | 1.1 | 6 |
| 503 | Digital arterial pressure pulse wave analysis and cardiovascular events in the general population: the Prevention of Renal and Vascular End-stage Disease study. Journal of Hypertension, 2020, 38, 1064-1071. | 0.3 | 6 |
| 504 | Ethnic differences in atrial fibrillation among patients with heart failure in Asia. ESC Heart Failure, 2020, 7, 1419-1429. | 1.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | Variation in human herpesvirus 6B telomeric integration, excision, and transmission between tissues and individuals. ELife, 2021, 10, . | 2.8 | 6 |
| 506 | Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. European Journal of Heart Failure, 2022, 24, 1009-1019. | 2.9 | 6 |
| 507 | High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 145-150. | 1.0 | 5 |
| 508 | Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2007, 8, 177-180. | 1.0 | 5 |
| 509 | Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria. American Journal of Cardiology, 2008, 102, 223-225. | 0.7 | 5 |
| 510 | Effects of Rosuvastatin on Coronary Flow Reserve and Metabolic Mismatch in Patients With Heart Failure (from the CORONA Study). American Journal of Cardiology, 2010, 105, 517-521. | 0.7 | 5 |
| 511 | Should erythropoietin treatment in chronic heart failure be haemoglobin targeted?. European Journal of Heart Failure, 2010, 12, 215-216. | 2.9 | 5 |
| 512 | The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure, 2012, 18, 883. | 0.7 | 5 |
| 513 | Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. American Heart Journal, 2014, 168, 354-362.e2. | 1.2 | 5 |
| 514 | Long-term cardiac abnormalities after cranial radiotherapy in childhood cancer survivors. Acta OncolÃ³gica, 2015, 54, 515-521. | 0.8 | 5 |
| 515 | CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. Journal of Cardiac Failure, 2015, 21, 939-940. | 0.7 | 5 |
| 516 | Associations between volume status and circulating microRNAs in acute heart failure. European Journal of Heart Failure, 2017, 19, 1077-1078. | 2.9 | 5 |
| 517 | A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. BMC Medicine, 2021, 19, 21. | 2.3 | 5 |
| 518 | Telomere length is independently associated with all-cause mortality in chronic heart failure. Heart, 2022, 108, 124-129. | 1.2 | 5 |
| 519 | Prevalence and predictive value of electrocardiographic abnormalities in pulmonary hypertension: evidence from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study. Cardiovascular Journal of Africa, 2017, 28, 370-376. | 0.2 | 5 |
| 520 | Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487. | 1.8 | 5 |
| 521 | Surrogate markers of gut dysfunction are related to heart failure severity and outcomeâ€“from the BIOSTAT-CHF consortium. American Heart Journal, 2022, 248, 108-119. | 1.2 | 5 |
| 522 | Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands. Journal of Medical Economics, 2006, 9, 121-131. | 1.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | Vascular benefits of angiotensin receptor blockers. Expert Opinion on Investigational Drugs, 2007, 16, 987-997. | 1.9 | 4 |
| 524 | Heart Failure in the Young. Journal of the American College of Cardiology, 2013, 62, 1855-1856. | 1.2 | 4 |
| 525 | Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure?. European Journal of Heart Failure, 2017, 19, 958-960. | 2.9 | 4 |
| 526 | Heart failure with midâ€range ejection fraction: causes and consequences. European Journal of Heart Failure, 2018, 20, 660-662. | 2.9 | 4 |
| 527 | Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. Clinical and Experimental Hypertension, 2018, 40, 637-643. | 0.5 | 4 |
| 528 | Is Time of the Essence? The Impact ofÂTime of Hospital Presentation in AcuteÂHeart Failure. JACC: Heart Failure, 2018, 6, 298-307. | 1.9 | 4 |
| 529 | Rapid right-sided deterioration in heart failure with preserved ejection fraction. European Heart Journal, 2019, 40, 699-702. | 1.0 | 4 |
| 530 | Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIANâ€HF registry. European Journal of Heart Failure, 2020, 22, 751-754. | 2.9 | 4 |
| 531 | Proenkephalin and the risk of newâ€onset heart failure: data from prevention of renal and vascular endâ€stage disease. Clinical Cardiology, 2021, , . | 0.7 | 4 |
| 532 | Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239. | 2.2 | 4 |
| 533 | Transcatheter edge-to-edge repair of tricuspid regurgitation in the Netherlands: state of the art and future perspectives. Netherlands Heart Journal, 2022, 30, 393-399. | 0.3 | 4 |
| 534 | Biomarker changes as surrogate endpoints in earlyâ€phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118. | 1.4 | 4 |
| 535 | Heart failure medication: moving from evidence generation to implementation. European Heart Journal, 2022, 43, 2588-2590. | 1.0 | 4 |
| 536 | Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, 161-168. | 1.0 | 3 |
| 537 | Statins and Autonomic Function in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2005, 19, 167-168. | 1.3 | 3 |
| 538 | Serum Erythropoietin Levels and Infarct Size. Journal of the American College of Cardiology, 2006, 47, 468-469. | 1.2 | 3 |
| 539 | The European Journal of Heart Failure in 2010: current impact factor, timeâ€toâ€first decision, and number of submissions. European Journal of Heart Failure, 2010, 12, 895-897. | 2.9 | 3 |
| 540 | Grading diastolic left ventricular function. European Journal of Heart Failure, 2011, 13, 698-699. | 2.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | The year in cardiology: heart failure 2014. European Heart Journal, 2015, 36, 421-424. | 1.0 | 3 |
| 542 | Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. Expert Opinion on Pharmacotherapy, 2016, 17, 1527-1538. | 0.9 | 3 |
| 543 | Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. European Journal of Heart Failure, 2020, 22, 903-906. | 2.9 | 3 |
| 544 | Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. Revista Espanola De Cardiologia (English Ed ), 2021, , . | 0.4 | 3 |
| 545 | Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. Clinical Cardiology, 2021, 44, 780-788. | 0.7 | 3 |
| 546 | HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY. Journal of the American College of Cardiology, 2013, 61, E749. | 1.2 | 2 |
| 547 | TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. Journal of the American College of Cardiology, 2017, 69, 766. | 1.2 | 2 |
| 548 | Sense and Sensibility of the Use of NT-proBNP for Eligibility in Clinical Trials. JACC: Heart Failure, 2018, 6, 257-259. | 1.9 | 2 |
| 549 | Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. International Journal of Cardiology, 2018, 253, 91-96. | 0.8 | 2 |
| 550 | Should Enrichment With NatriureticÂPeptide Levels Be Mandatory in Global Clinical Trials?. JACC: Heart Failure, 2020, 8, 369-371. | 1.9 | 2 |
| 551 | Effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 1049-1052. | 2.9 | 2 |
| 552 | Prognostic Value of Pulse Pressure in Heart Failure. Journal of Cardiac Failure, 2007, 13, 694. | 0.7 | 1 |
| 553 | Effects of Eprosartan on Diastolic Function and Neurohormones in Patients with Hypertension and Diastolic Dysfunction. Cardiovascular Drugs and Therapy, 2010, 24, 33-40. | 1.3 | 1 |
| 554 | Novel biomarkers for prediction of poor treatment response in heart failure to guide therapy. Lancet, The, 2014, 383, S32. | 6.3 | 1 |
| 555 | The Fastest Way to the Failing Heart Is Through the Kidneys. JACC: Heart Failure, 2017, 5, 682-683. | 1.9 | 1 |
| 556 | Quantifying the HDL proteome by mass spectrometry: how many proteins truly associate with HDL? Reply. European Journal of Heart Failure, 2018, 20, 1077-1078. | 2.9 | 1 |
| 557 | Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?. Circulation, 2019, 139, 2383-2385. | 1.6 | 1 |
| 558 | Discussion forum response to Canepa et al. European Heart Journal, 2019, 40, 705-706. | 1.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model. European Journal of Heart Failure, 2002, 4, 277-282. | 2.9 | 0 |
| 560 | Response to Letter Regarding Article, â€œEndogenous Erythropoietin and Outcome in Heart Failureâ€. Circulation, 2010, 122, . | 1.6 | 0 |
| 561 | Trial data resolve gaps in evidence-based treatment. Nature Reviews Cardiology, 2013, 10, 67-68. | 6.1 | 0 |
| 562 | Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. Journal of Cardiac Failure, 2014, 20, S93. | 0.7 | 0 |
| 563 | Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536. | 1.2 | 0 |
| 564 | Lessons Learned and to Be Learned About the Use of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure and Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, . | 1.6 | 0 |
| 565 | Risk stratification in acute heart failure: reply. European Journal of Heart Failure, 2018, 20, 945-947. | 2.9 | 0 |
| 566 | Time to Revisit the Value of UrineÂCollections in Heart Failure. JACC: Heart Failure, 2019, 7, 392-393. | 1.9 | 0 |
| 567 | What is the added value of the waistâ€toâ€hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply. European Journal of Heart Failure, 2019, 21, 132-133. | 2.9 | 0 |
| 568 | Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. Journal of Cardiac Failure, 2020, 26, 1108-1109. | 0.7 | 0 |
| 569 | Drug development in oncology and devicesâ€"lessons for heart failure drug development and approval? a review. Heart Failure Reviews, 2021, 26, 255-262. | 1.7 | 0 |
| 570 | Is There Any Interaction Between Sex and Renal Function Change During Hospital Stay in Patients Hospitalized With Acute Heart Failure?. Journal of Cardiac Failure, 2021, 27, 934-941. | 0.7 | 0 |
| 571 | Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study. American Heart Journal, 2021, 244, 36-41. | 1.2 | 0 |
| 572 | Abstract 11150: Albuminuria in Heart Failure is More Strongly Associated with Markers of Congestion Than Renal Dysfunction. Circulation, 2021, 144, . | 1.6 | 0 |
| 573 | Abstract 11074: Worsening Renal Function in Acute Heart Failure in the Context of Diuretic Response. Circulation, 2021, 144, . | 1.6 | 0 |
| 574 | 128â€ƒClinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. European Heart Journal Supplements, 2021, 23, . | 0.0 | 0 |
| 575 | Risk factors for the development of heart failure in patients with or without prior myocardial infarction. European Journal of Heart Failure, 2022, 24, 985-987. | 2.9 | 0 |
| 576 | Abstract 12543: Limited Blood Biomarker Changes After Reverse Remodelling: A Markers and Response to CRT (Marc) Substudy. Circulation, 2021, 144, . | 1.6 | 0 |